June 23, 2008 -- According to Reuters, Bayer AG (FSE: BAYA) thinks it can become the biggest seller of prescription drugs in China this year, bypassing AstraZeneca (NYSE: AZN), which is currently the top dog. Arthur J. Higgins, the head of Bayer Healthcare, said that revenues in China are growing at more than 40% annually. In 2008, they will top $500 million for the Germany-based pharma giant. More details...
